The US FDA may in the future look to increase prosecution of "responsible corporate officials" in both the pharmaceutical and food industry, Commissioner Margaret Hamburg has stated in a letter, which followed a scathing new government.....

Establishments that produce substandard or counterfeit antimalarials will find it harder to sell their products to developing countries after the World Health Organization published new guidelines this week spelling out how to buy.....

Around 300 products will escape a reduction in the next regular revision of reimbursement prices for prescription drugs in Japan on April 1st because they meet certain criteria under complex new rules being adopted on a trial basis this.....

Abbott has succeeded where Biogen Idec failed last year in having a takeover offer accepted by Facet Biotech.

Abbott will pay $27 per share for Facet, which values the biotech at $722 million minus its cash and marketable.....

http://www.scripnews.com/middle_east_clinical_trials/

The attractions of the Middle East as a location for clinical research include patient diversity,.....

The US Supreme Court said in a one-sentence order on March 8th that it has granted review to the plaintiffs in a case known as Bruesewitz v Wyeth, a test of the scope of the pre-emption provision of the National Childhood Vaccine Injury Act of.....

Sales of human pharmaceuticals in Estonia fell by 1% to EEK 3 billion ($258 million) in wholesale prices last year compared with 2008, the state agency of medicines, Ravimiamet, has said.

Growth in the country's pharmaceutical market has been.....

GlaxoSmithKline intends to stay away from "pure generics" in Western markets, even as it outlined its intent to expand organically as well as through potential acquisitions in India.

GSK chief executive Andrew Witty, who was in.....

AstraZeneca is facing more disappointment with the development of its new anticancers after its experimental anti-angiogenic drug Recentin (cediranib) did not show non-inferiority in progression-free survival (PFS), or superiority, to .....

Lexicon Pharmaceuticals has announced plans to offer for sale $95 million of its common stock in an underwritten public offering. It could also sell up to $14.25 million worth of shares as an over-allotment option.

Lexicon expects.....

The UK firm Vernalis has regained full rights to the royalties on its only marketed product, the migraine treatment frovatriptan. It made a one-off net cash payment of $32.57 million to Paul Capital Healthcare (PCH), which acquired 2.1 million.....

Slovakia’s association of research-based pharmaceutical companies (SAFS) has elected a new board. Dr Pavol Trnovec of GlaxoSmithKline, who was previously its vice-chairman, will lead SAFS as chairman. He replaces Dr Miroslav Lednar.....

Sanofi-Aventis has exercised its option to combine its animal health business Merial with Intervet/Schering-Plough Animal Health, Merck & Co's animal health unit.

Sanofi-Aventis bought out Merck's 50% share in Merial for $4.....

Polpharma, one of Poland's largest pharmaceutical manufacturers, is buying an antibiotics production business from Bioton, another local company, for PLN 80 million ($8 million). Poland's office of competition and consumer protection has approved the.....

XenoPort is shedding 50% of its workforce and shelving its discovery research efforts following the "unexpected setback" in the approval of Horizant (XP13512; gabapentin enacarbil extended release tablets), which is under development with.....

The US FDA recognises emerging and pandemic threats – and it aims to boost the development of cell-based viral vaccines with the publication of a final guidance entitled Guidance for Industry: Characterization and Qualification of Cell.....